References
- International Association for the Study of Pain. IASP Taxonomy. United States: IASP; 1994
- Smith BH, Torrance N, Ferguson JA, et al. Towards a definition of refractory neuropathic pain for epidemiological research. An international Delphi survey of experts. BMC Neurol 2012;12:29
- International Association for the Study of Pain. Epidemiology of neuropathic pain: how common is neuropathic pain, and what is its impact? United States: IASP; 2014
- Sicras-Mainar A, Rejas-Gutierrez J, Perez-Paramo M, et al. Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity. J Eval Clin Pract 2017;23:402-12
- National Health Service (NHS). Neuropathic pain: pregabalin and gabapentin prescribing. PrescQIPP. United Kingdom: NHS; 2016
- National Institute for Health and Care Excellence (NICE). Clinical guideline [CG173] - Neuropathic pain in adults: pharmacological management in non-specialist settings. United Kingdom: NICE; 2017
- McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006;10:127
- Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88
- Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19
- Sullivan W, Hirst M, Beard S, et al. Economic evaluation in chronic pain: a systematic review and de novo flexible economic model. Eur J Health Econ 2016;17:755-70
- National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. United Kingdom: NICE; 2013
- Critchlow S, Hirst M, Akehurst R, et al. A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future. J Med Econ 2017;20:129-39
- Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making 2012;32:667-77
- Dunlop WCN, Mason N, Kenworthy J, et al. Benefits, challenges and potential strategies of open source health economic models. Pharmacoeconomics 2017;35:125-8
- Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making 2012;32:733-43
- Baio G, Heath A. When simple becomes complicated: why Excel should lose its place at the top table. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. London, United Kingdom. 2018
- Cohen JT, Neumann PJ, Wong JB. A Ccall for open-source cost-effectiveness analysis. Ann Intern Med 2017;167:432-3
- R Core Team. A language and environment for statistical computing 2016. Vienna, Austria: The R Foundation. Available from: https://www.r-project.org/ [Last accessed 2 October 2017]
- Personal Social Services Research Unit (PSSRU). Unit costs of health and social care. United Kingdom: PSSRU; 2012
- National Health Service (NHS). Electronic Drug Tariff. United Kingdom: NHS; 2013
- Personal Social Services Research Unit (PSSRU). The hospital and community health services (HCHS) index. United Kingdom: PSSRU; 2014
- International Association for the Study of Pain. What is neuropathic pain? United States: IASP; 2014
- Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005;9:1-157, iii–iv
- Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 1998;48:25-36
- Sullivan SD, Lew DP, Devine EB, et al. Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics 2002;20:1079-89
- National Institute for Health and Care Excellence (NICE). Clinical guideline [CG173] - Appendix F Full health economic report. United Kingdom: NICE; 2017
- Dworkin RH, Turk DC, McDermott MP, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 2009;146:238-44